A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Summary

Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with or without other Investigational Medicinal Products (IMPs), will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks until complete response or disease worsening/progressing.

Timeline

Start

2007-05

Primary completion

2008-12

Completion

2008-12

Drugs

Indications